Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2
Baraliakos X, Ramiro S, Magrey M, Rudwaleit M, Haroon N, Fleurinck C, Massow U, De Peyrecave N, Vaux T, Marzo-Ortega H, Navarro-Compán V (2023)
Annals of the Rheumatic Diseases 82(Suppl. 1): 875-876.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Baraliakos, X.;
Ramiro, S.;
Magrey, M.;
Rudwaleit, MartinUniBi;
Haroon, N.;
Fleurinck, C.;
Massow, U.;
De Peyrecave, N.;
Vaux, T.;
Marzo-Ortega, H.;
Navarro-Compán, V.
Einrichtung
Stichworte
Spondyloarthritis;
Clinical trials;
Treat to target
Erscheinungsjahr
2023
Serien- oder Zeitschriftentitel
Annals of the Rheumatic Diseases
Band
82
Ausgabe
Suppl. 1
Seite(n)
875-876
Konferenz
European Congress of Rheumatology (EULAR)
Konferenzort
Milan, ITALY
Konferenzdatum
2023-05-31 – 2023-06-03
ISSN
0003-4967
eISSN
1468-2060
Page URI
https://pub.uni-bielefeld.de/record/2987168
Zitieren
Baraliakos X, Ramiro S, Magrey M, et al. Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2. Annals of the Rheumatic Diseases. 2023;82(Suppl. 1):875-876.
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, M., Haroon, N., Fleurinck, C., Massow, U., et al. (2023). Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2. Annals of the Rheumatic Diseases, 82(Suppl. 1), 875-876. https://doi.org/10.1136/annrheumdis-2023-eular.833
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, Martin, Haroon, N., Fleurinck, C., Massow, U., et al. 2023. “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2”, Annals of the Rheumatic Diseases, 82 (Suppl. 1): 875-876.
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, M., Haroon, N., Fleurinck, C., Massow, U., De Peyrecave, N., Vaux, T., Marzo-Ortega, H., et al. (2023). Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2. Annals of the Rheumatic Diseases 82, 875-876.
Baraliakos, X., et al., 2023. Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2. Annals of the Rheumatic Diseases, 82(Suppl. 1), p 875-876.
X. Baraliakos, et al., “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 875-876.
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, M., Haroon, N., Fleurinck, C., Massow, U., De Peyrecave, N., Vaux, T., Marzo-Ortega, H., Navarro-Compán, V.: Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2. Annals of the Rheumatic Diseases. 82, 875-876 (2023).
Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, Martin, Haroon, N., Fleurinck, C., Massow, U., De Peyrecave, N., Vaux, T., Marzo-Ortega, H., and Navarro-Compán, V. “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2”. Annals of the Rheumatic Diseases 82.Suppl. 1 (2023): 875-876.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar